Navigation Links
NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk

GAITHERSBURG, Maryland and HILDEN, Germany, October 18 /PRNewswire/ -- The first randomized, controlled study in North America of HPV testing as a stand-alone screen concluded that it is almost 40 percent more accurate than traditional cytology (the Pap "smear") in identifying women with advanced cervical disease, according to a report published today in The New England Journal of Medicine.

The study, which involved more than 10,000 Canadian women age 30-69, found that the HPV test's sensitivity - its ability to accurately identify women with pre-cancerous cervical cells or cancer - was 94.6 percent, compared to 55.4 percent for the Pap. HPV (humanpapilloma virus) is the primary cause of cervical cancer.

This seminal study used QAIGEN's Hybrid Capture(R) 2 High-Risk HPV DNA test -- the only such test that is both CE-marked in Europe and approved by the U.S. Food and Drug Administration(1). The molecular diagnostic test was developed by Digene Corp., now part of QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA). The performance of QIAGEN's HPV test has been validated in studies that included more than 300,000 women.

"We already knew before conducting this study that the sensitivity of the Pap left a lot to be desired," stated one of the study's authors, Eduardo Franco, DrPH, of Montreal's McGill University, in a news announcement. "However, 55.4 percent accuracy is only slightly above chance. Flipping a coin gives you 50 percent."

Participants in the Canadian Cervical Cancer Screening Trial (CCCaST) were randomly assigned to a "focus on Pap" or "focus on HPV" screening group, although for ethical reasons, both groups received both tests. In this study, conventional cytology was used. Recent analyses have found that the newer "liquid-based" cytology does not significantly improve the ability to detect disease. All CCCaST participants who tested positive on either the Pap or HPV test were referred for a follow-up biopsy. In addition to the HPV test's greater sensitivity, the study found that its specificity - the likelihood that women with positive results actually have disease - was only slightly less than the Pap's (94.1 percent vs. 96.8 percent).

HPV testing for routine cervical cancer prevention is currently most widely practiced in the United States, where it is approved for use along with a Pap in women age 30 and over. Under the currently recommended guidelines, screening that includes HPV testing may be performed at longer intervals than when the Pap is used alone. However, the authors of the NEJM report concluded that co-testing "only marginally improved sensitivity compared with HPV testing alone".

The conclusions of CCCaST reinforce a growing number of other studies showing greater sensitivity for HPV testing and suggesting its use as the primary, front-line screen -- with the Pap reserved for follow-up evaluation.(2) For example, most recently, the Oct. 4 issue of The Lancet reported on a trial involving more than 17,000 women in the Netherlands. The study, led by Professor Chris Meijer of VU Medical Centre in Amsterdam, concluded that HPV DNA testing detects pre-cancerous cervical cells earlier than the traditional Pap, thus allowing longer intervals between screenings. This is an important feature for health authorities working to control costs - particularly those in developing countries, where a variety of obstacles make it difficult for women to access regular medical care.

Medical experts agree that the most effective approach to cervical cancer prevention combines HPV vaccines for girls and young women with screening of older women.

"We believe that a shift from cellular to viral (screening) tests, coupled with education and vaccination, will contribute to more efficient control of cervical cancer," the authors stated in the NEJM report.

About HPV and cervical cancer

Worldwide, cervical cancer affects more than 400,000 women annually and, after breast cancer, is the second-most-common malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causing problems. It is only infections that persist that can cause abnormal cells to form that may develop into cervical cancer if not detected and treated early.


QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions. The company's products are sold to academic research markets, leading pharmaceutical and biotechnology companies, applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) and molecular diagnostics laboratories. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries; the company employs more than 2,600 people worldwide. Further information about QIAGEN can be found at Further information about HPV DNA testing can be found at

(1) The hc2 High Risk HPV test has been approved by the Food and Drug Administration for the follow-up evaluation of women with ASC-US (inconclusive) cytology and for use as an adjunctive test combined with the Pap to screen women age 30 years and older.

(2) This information is provided as a summary of several clinical studies. The use of the Hybrid Capture(R) High-Risk HPV DNA Test as a stand-alone screen for cervical cancer has not been approved by the U.S. Food and Drug Administration.

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. No harm in reducing prenatal check up to 3 - 6 times says WHO report
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Report on the Safety and Effectiveness of Melatonin supplements
6. WHO report asks for improved healthcare for mother and child
7. Research reports that c-section deliveries are rising
8. Jharkhand reports 13,000 Malaria cases
9. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
10. Experts Insist That Neonatal Herpes Be Reported Regularly
11. Uganda Reports Failure To Contain Sleeping Sickness
Post Your Comments:
(Date:10/13/2015)... ... 2015 , ... Georgia Partnership for TeleHealth (GPT), ... along with affiliate organizations, Alabama Partnership for Telehalth (ATP) and Florida Partnership for ... 2015. , Each of the three conferences share this year’s conference theme, ...
(Date:10/13/2015)... Cheyenne, Wyoming (PRWEB) , ... October 13, 2015 , ... ... at the Gold’s Gym International Conference on August 26. Berry, who owns and operates ... exemplary standards for the fastest growing Gold’s Gyms in the United States. A brand ...
(Date:10/13/2015)... ... ... With Fall weather approaching and holiday travel season upon us, is giving ... Enter to win! , How to Enter:, 1. Like on Facebook , ... Follow us on Instagram @thebeautyplace , 4. Share Facebook Contest Image With Friends ...
(Date:10/13/2015)... ... October 13, 2015 , ... Bambeco, ... furnishings and décor, today announced it closed on a $20.5 million funding round ... be used to support the Company’s continued rapid growth and expansion, broaden the ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... National Women’s show this coming October in Toronto, an exhibition featuring the newest ... to choose from, Curly Hair Solutions® couldn’t be more excited to unveil their ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Asterias Biotherapeutics, ... with the UK-based Cell Therapy Catapult to advance ... Asterias, allogeneic dendritic cell immunotherapy. Under the agreement, ... manufacturing processes for AST-VAC2 to support advanced clinical ... --> --> The Cell ...
(Date:10/12/2015)... , Oct. 12, 2015 Given ... it is quite challenging to deliver an ophthalmic drug effectively ... overcome for a successful ocular drug delivery. These include dilution ... the lymphatic system of conjunctiva and drug permeation issues with ... the drug, in topical eye drops, is lost due to ...
(Date:10/12/2015)... Use this report to: - Learn about ... medical membrane devices market. - Analyze the present and ... membrane devices market including hemodialyzers, membrane oxygenators, intravenous infusion ... - Gain information on newly approved products, recalls and ... this report to: - Learn about the performance, the ...
Breaking Medicine Technology: